Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued ...

About Mantle Cell Lymphoma (MCL) MCL is an aggressive, incurable type of blood cancer that spreads quickly and originates from the B lymphocytes, ... Clinically Active BTK Inhibitor PCI-32765 Targets ...

Panelists discuss the primary access challenges in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) treatment, including financial barriers and health care system limitations, and ...

New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant ...

Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...

Mantle cell lymphoma (MCL) is an aggressive, incurable B-cell lymphoma. 1-3 Chemoimmunotherapy typically followed by autologous stem-cell transplant has been the standard of care in young, fit ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.